2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alexander B. Olawaiye, MD, discusses front line treatment sequencing considerations in ovarian cancer.
Alexander B. Olawaiye, MD, director, Gynecologic Oncology Research Program, professor, Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, Magee-Women’s Hospital, the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses front line treatment sequencing considerations in ovarian cancer.
The ovarian cancer treatment landscape currently faces the unique problem of having several agents available for treatment in the frontline setting, Olawaiye says. Due to the various treatment choices, it is crucial for clinicians to monitor the latest data when deciding between certain treatments, Olawaiye explains.
Patient costs, including those beyond monetary expenses, need to be factored into treatment decisions for this patient population, Olawaiye continues. Using the data and examining potential toxicities are important steps toward identifying the proper treatment for each patient, Olawiaye concludes.